International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Vaccine

Volumn 29, Issue 32, 2011, Pages 5203-5209

  Barouch, Dan H ^a,b   Kik, Sandra V ^c   Weverling, Gerrit J ^c   Dilan, Rebecca ^a   King, Sharon L ^a   Maxfield, Lori F ^a   Clark, Sarah ^a   Ng'ang'a, David ^a   Brandariz, Kara L ^a   Abbink, Peter ^a   Sinangil, Faruk ^d   de Bruyn, Guy ^e   Gray, Glenda E ^e   Roux, Surita ^f   Bekker, Linda Gail ^f   Dilraj, Athmanundh ^g   Kibuuka, Hannah ^h   Robb, Merlin L ⁱ   Michael, Nelson L ⁱ   Anzala, Omu ^j   Amornkul, Pauli N ^k   Gilmour, Jill ^k,l   Hural, John ^m   Buchbinder, Susan P ⁿ   Seaman, Michael S ^a   Dolin, Raphael ^a   Baden, Lindsey R ^o   Carville, Angela ^p   Mansfield, Keith G ^p   Pau, Maria G ^c   Goudsmit, Jaap ^c   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

^d Global Solutions for Infectious Diseases   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h Makerere University   (Uganda)

ⁱ WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^j UNIVERSITY OF NAIROBI   (Kenya)

^k INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m USA   (United States)

ⁿ SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^o BRIGHAM AND WOMEN S HOSPITAL   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Adenovirus; HIV 1; Vaccine; Vector

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENOVIRUS; ADENOVIRUS 26; ADENOVIRUS 35; ADENOVIRUS 48; ADENOVIRUS 5; ADULT; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROEPIDEMIOLOGY;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADULT; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CHILD; HIV-1; HUMANS; INFANT; MACACA MULATTA; VACCINES, SYNTHETIC; VIRAL VACCINES; YOUNG ADULT;

EID: 79960298256     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.025     Document Type: Article

References (23)

1. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77(11 (June)):6305-6313.
2. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(7090 (May 11)):239-243.
3. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653 (November 29)):1881-1893.
4. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46(11 (June 1)):1769-1781.
5. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194(12 (December 15)):1638-1649.
6. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77(15 (August)):8263-8271.
7. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172(10 (May 15)):6290-6297.
8. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007, 81 (May)(9):4654-4663.
9. Farina S.F., Gao G.P., Xiang Z.Q., Rux J.J., Burnett R.M., Alvira M.R., et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001, 75(23 (December)):11603-11613.
10. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170(3 (February 1)):1416-1422.
11. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132(3 (February 8)):397-409.
12. Lore K., Adams W.C., Havenga M.J., Precopio M.L., Holterman L., Goudsmit J., et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007, 179(3 (August 1)):1721-1729.
13. Liu J., Ewald B.A., Lynch D.M., Denholtz M., Abbink P., Lemckert A.A., et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008, 82(10 (May)):4844-4852.
14. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(7225 (January 1)):87-91.
15. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., Lemckert A.A., et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006, 44(10 (October)):3781-3783.
16. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28(4 (January 22)):950-957.
17. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004, 18(8 (May 21)):1213-1216.
18. Curlin M.E., Huang M.L., Lu X., Celum C.L., Sanchez J., Selke S., et al. Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men. PLoS One 2010, 5(6):e11321.
19. Chen H., Xiang Z.Q., Li Y., Kurupati R.K., Jia B., Bian A., et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 2010, 84(20 (October)):10522-10532.
20. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003, 41(11 (November)):5046-5052.
21. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(9653 (November 29)):1894-1905.
22. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194(12 (December 15)):1661-1671.
23. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5 (March 1)):654-665.